Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A What and how can we do better?

被引：0
作者：
Scharf, Ruediger E. [1 ,2 ,3 ]
机构：
[1] Univ Dusseldorf, Med Ctr, Dept Expt & Clin Hemostasis, Hemotherapy & Transfus Med, Dusseldorf, Germany
[2] Univ Dusseldorf, Med Ctr, Hemophilia Comprehens Care Ctr, Dusseldorf, Germany
[3] Univ Dusseldorf, Biol Med Res Ctr, Dusseldorf, Germany
来源：
HAMOSTASEOLOGIE | 2016年 / 36卷 / 03期
关键词：
RECOMBINANT FACTOR-VIII; B-DOMAIN DELETION; BISPECIFIC ANTIBODY; IMMUNOGENICITY; INHIBITORS; ACE910; MODEL; LIFE; PRODUCTS; BLEEDS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：195 / 198
页数：4
相关论文
共 18 条
[1]   Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII [J].
Aledort, L. M. ;
Navickis, R. J. ;
Wilkes, M. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) :2325-2327
[2]   Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies [J].
Aledort, L. M. ;
Navickis, R. J. ;
Wilkes, M. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) :2180-2192
[3]   Is the incidence and prevalence of inhibitors greater with recombinant products? Yes [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (06) :861-862
[4]   Hemophilia Therapy - Navigating Speed Bumps on the Innovation Highway [J].
DiMichele, Donna M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (21) :2087-2089
[5]   Factor VIII Products and Inhibitor Development in Severe Hemophilia A [J].
Gouw, Samantha C. ;
van der Bom, Johanna G. ;
Ljung, Rolf ;
Escuriola, Carmen ;
Cid, Ana R. ;
Claeyssens-Donadel, Segolene ;
van Geet, Christel ;
Kenet, Gili ;
Makipernaa, Anne ;
Molinari, Angelo Claudio ;
Muntean, Wolfgang ;
Kobelt, Rainer ;
Rivard, George ;
Santagostino, Elena ;
Thomas, Angela ;
van den Berg, H. Marijke .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03) :231-239
[6]   Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom [J].
Hay, Charles R. M. ;
Palmer, Ben ;
Chalmers, Elizabeth ;
Liesner, Ri ;
Maclean, Rhona ;
Rangarajan, Savita ;
Williams, Michael ;
Collins, Peter W. .
BLOOD, 2011, 117 (23) :6367-6370
[7]   A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model [J].
Kitazawa, Takehisa ;
Igawa, Tomoyuki ;
Sampei, Zenjiro ;
Muto, Atsushi ;
Kojima, Tetsuo ;
Soeda, Tetsuhiro ;
Yoshihashi, Kazutaka ;
Okuyama-Nishida, Yukiko ;
Saito, Hiroyuki ;
Tsunoda, Hiroyuki ;
Suzuki, Tsukasa ;
Adachi, Hideki ;
Miyazaki, Taro ;
Ishii, Shinya ;
Kamata-Sakurai, Mika ;
Iida, Takeo ;
Harada, Aya ;
Esaki, Keiko ;
Funaki, Miho ;
Moriyama, Chifumi ;
Tanaka, Eriko ;
Kikuchi, Yasufumi ;
Wakabayashi, Tetsuya ;
Wada, Manabu ;
Goto, Masaaki ;
Toyoda, Takeshi ;
Ueyama, Atsunori ;
Suzuki, Sachiyo ;
Haraya, Kenta ;
Tachibana, Tatsuhiko ;
Kawabe, Yoshiki ;
Shima, Midori ;
Yoshioka, Akira ;
Hattori, Kunihiro .
NATURE MEDICINE, 2012, 18 (10) :1570-U177
[8]   To clear or to fear: An innate perspective on factor VIII immunity [J].
Lai, Jesse Derek ;
Georgescu, Maria Teofana ;
Hough, Christine ;
Lillicrap, David .
CELLULAR IMMUNOLOGY, 2016, 301 :82-89
[9]   Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A [J].
Leissinger, C. ;
Cooper, D. L. ;
Solem, C. T. .
HAEMOPHILIA, 2011, 17 (06) :884-889
[10]   Factor VIII inhibitors in previously treated hemophilic patients [J].
Mannucci, P. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) :2328-2329
12